Evaluation of cardiovascular changes in dogs administered three positive controls using jacketed external telemetry-blood pressure (JET-BP)

Journal of Pharmacological and Toxicological Methods

Volumn 75, Issue , 2015, Pages 27-37

  Kremer, John J ^a   Bills, Andrew J ^a   Hanke, Nathanael J ^a   Chen, Hepei ^a   Meier, William A ^a   Osinski, Mark A ^a   Foley, C Michael ^a  

^a Late Stage Developmental Services Covance Inc   (United States)

Author keywords

Blood pressure; Cardiovascular; Dogs; Electrocardiography; Methods; Nonclinical; Power analysis; QT interval; Safety pharmacology; Telemetry

Indexed keywords

ETILEFRINE; HYDRALAZINE; SOTALOL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEAGLE; BLOOD PRESSURE; BLOOD PRESSURE MONITOR; CARDIOTOXICITY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG BLOOD LEVEL; ELECTROCARDIOGRAPHY; FEMALE; FUNCTIONAL ASSESSMENT; HEART RATE; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PULSE PRESSURE; QT PROLONGATION; SYSTOLIC BLOOD PRESSURE; TELEMETRY; ANIMAL; DOG; DRUG EFFECTS; METHODOLOGY; PRECLINICAL STUDY; PROCEDURES;

ANIMALS; BLOOD PRESSURE; CARDIOTOXICITY; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; ELECTROCARDIOGRAPHY; ETILEFRINE; FEMALE; HYDRALAZINE; MALE; RESEARCH DESIGN; SOTALOL; TELEMETRY;

EID: 84942552531     PISSN: 10568719     EISSN: 1873488X     Source Type: Journal    
DOI: 10.1016/j.vascn.2015.05.008     Document Type: Article

References (40)

1. Aw T.J., Haas S.J., Liew D., Krum H. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Archives of Internal Medicine 2005, 165:490-496.
2. Baird T.J., Bailie M., Patrick D.J., Moddrelle D., Yoder J., Gauvin D.V., et al. Influence of surgically implantable telemetry solutions on in-life and postmortem toxicology endpoints. Journal of Pharmacological and Toxicological Methods 2013, 67(3):148-161.
3. Berridge B.R., Hoffmann P., Turk J.R., Sellke F., Gintant G., Hirkaler G., et al. Integrated and translational nonclinical in vivo cardiovascular risk assessment: Gaps and opportunities. Regulatory Toxicology and Pharmacology 2013, 65(1):38-46.
4. Chain A.S.Y., Dubois V.F.S., Danhof M., Sturkenboom M.C.J.M., Della Pasqua O. Identifying the translational gap in the evaluation of drug-induced QTc interval prolongation. British Journal of Clinical Pharmacology 2013, 76:708-724.
5. Chui R.W., Fosdick A., Conner R., Jiang J., Bruenner B.A., Vargas H.M. Assessment of two external telemetry systems (Physiojacket™ and JET™) in beagles with telemetry implants. Journal of Pharmacological and Toxicological Methods 2009, 60:58-68.
6. Ewart L., Milne A., et al. A multi-site comparison of in vivo safety pharmacology studies conducted to support ICH S7A & B regulatory submissions. Journal of Pharmacological and Toxicological Methods 2013, 68:30-43.
7. Gauvin D.V., Tilley L.P., Smith F.W.K., Baird T.J. Electrocardiogram, hemodynamics, and core body temperatures of the normal free moving laboratory beagle dog by remote radiotelemetry. Journal of Pharmacological and Toxicological Methods 2006, 53:128-139.
8. Greaves P. Patterns of drug-induced cardiovascular pathology in the beagle dog: Relevance for humans. Experimental and Toxicological Pathology 1998, 50:283-293.
9. Guth B. Preclinical cardiovascular risk assessment in modern drug development. Toxicological Sciences 2007, 97(1):4-20.
10. Guth B.D., Bass A.S., Briscoe R., Chivers S., Markert M., Siegl P.K.S., et al. Comparison of electrocardiographic analysis for risk of QT interval prolongation using safety pharmacology and toxicology studies. Journal of Pharmacological and Toxicological Methods 2009, 56:107-116.
11. Hanton G., Rabemampianina Y. The electrocardiogram of the beagle dog: Reference values and effect of sex, genetic strain, body position, and heart rate. Laboratory Animals 2006, 40:123-136.
12. Heath B.M., Cui Y., Worton S., Lawton B., Ward G., Ballini E., et al. Translation of flecainide- and mexiletine-induced cardiac sodium channel inhibition and ventricular conduction slowing from nonclinical models to clinical. Journal of Pharmacological and Toxicological Methods 2011, 63:258-268.
13. ICH (International Conference on Harmonisation) S7A guidance. Safety pharmacology studies for human pharmaceuticals 2001, July.
14. ICH (International Conference on Harmonisation) S9 guidance. Nonclinical evaluation for anticancer pharmaceuticals 2010, March.
15. ICH (International Conference on Harmonisation) M3R2 guidance. Nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals 2010 January.
16. ICH (International Conference on Harmonisation) S6(R1) guidance. Preclinical safety evaluation of biotechnology-derived pharmaceuticals 2011, June.
17. Kurtz T.W., Grifflin K.A., Bidani A.K., Davisson R.L., Hall J.E. Recommendations for blood pressure measurement in humans and experimental animals. Part 2: Blood pressure measurement in experimental animals: a statement for professionals from the subcommittee of professional and public education of the American Heart Association council on high blood pressure research. Hypertension 2005, 45:299-310.
18. Laverty H.G., Benson C., Cartwright E.J., Cross M.J., Garland C., Hammond T., et al. How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines?. British Journal of Pharmacology 2011, 163:679-693.
19. Ledwith B.J., Degeorge J.J. Changes to ICH guideline M3: new and revised guidance on nonclinical safety studies to support human clinical trials and marketing authorization. Clinical Pharmacology and Therapeutics 2011, 89(2):295-299.
20. Leishman D.J., Beck T.W., Dybdal N., Gallacher D.J., Guth B.D., Holbrook M., et al. Best practice in the conduct of key nonclinical cardiovascular assessments in drug development: Current recommendations from the Safety Pharmacology Society. Journal of Pharmacological and Toxicological Methods 2012, 65:93-101.
21. Lewington S., Clarke R., Qizilbash N., Peto R., Collins R. Prospective Studies Collaboration: Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002, 366:1903-1913.
22. Maekawa K., Liang C.-S., Tsui A., Chen B.T., Kawashima S. Vasodilative effect of hydralazine in awake dogs: The roles of prostaglandins and the sympathetic nervous system. Circulation 1984, 70:908-916.
23. McKee J., Daller J., Baumgartner B., Pettinger S. Evaluation of the sensitivity of a new fully implantable telemetry device and the importance of simultaneously measuring cardiac output and left ventricular pressure. Journal of Pharmacological and Toxicological Methods 2014, 69:229-236.
24. McMahon C., Mitchell A.Z., Klein J.L., Jenkins A.C., Sarazan R.D. Evaluation of blood pressure measurement using a miniature blood pressure transmitter with jacketed external telemetry in cynomolgus monkeys. Journal of Pharmacological and Toxicological Methods 2010, 62:127-135.
25. Meyer O., Jenni R., Greiter-Wilke A., Breifenbach A., Holzgrefe H.H. Comparison of telemetry and high-definition oscillometry for blood pressure measurements in conscious dogs: Effects of torcetrapib. Journal of the American Association for Laboratory Animal Science 2010, 49(4):464-471.
26. Mitchell A.M., Bills A.J., Wittwer G.T., Foley C.M., Kremer J.J., Chen H., et al. Intravenous solid tip ECG lead placement in telemetry implanted dogs is less invasive but produces comparable signal quality to epicardial leads. Journal of Pharmacological and Toxicological Methods 2013, 68:62-73.
27. Mitchell A.M., McMahon C., Beck T.W., Sarazan R.D. Sensitivity of two noninvasive blood pressure measurement techniques compared to telemetry in cynomolgus monkeys and beagles. Journal of Pharmacological and Toxicological Methods 2010, 62:54-63.
28. Olson H., Betton G., Robinson D., Thomas K., Monro A., Kolaja G., et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regulatory Toxicology and Pharmacology 2000, 32:56-67.
29. Parkinson J., Visser S.A.G., Jarvis P., Pollard C., Valentin J.-P., Yates J.W.T., et al. Translational pharmacokinetic-pharmacodynamic modeling of QTc effects in dog and human. Journal of Pharmacological and Toxicological Methods 2013, 68:357-366.
30. Polakowski J.S., King A.J., Campbell T.J., Nelson R.A., Preusser L.C., Kempf-Grote A.J., et al. Cardiovascular effects of torcetrapib in conscious and pentobarbital anesthetized dogs. Journal of Cardiovascular Pharmacology 2009, 54(6):543-551.
31. Prior H., McMahon N., Schofield J., Valentin J.-P. Non-invasive telemetric electrocardiogram assessment in conscious beagles. Journal of Pharmacological and Toxicological Methods 2009, 60:167-173.
32. Redfern W.S., Ewart L.C., Lainée P., Pinches M., Robinson S., Valentin J.-P. Functional assessments in repeat-dose toxicity studies: the art of the possible. Toxicology Research 2013, 2:209-234.
33. Redfern W.S., Ewart L., Hammond T.G., Bialecki R., Kinter L., Lindgren S., et al. Impact and frequency of different toxicities throughout the pharmaceutical life cycle. The Toxicologist 2010, 114(S-1):1081.
34. Schmelting B., Niehoff M., Egner B., Korte S.H., Weinbauer G.F. High definition oscillometry: A novel technique for non-invasive blood pressure monitoring in the cynomolgus monkey (Macaca fascicularis). Journal of Medical Primatology 2009, 38:293-301.
35. Soloviev M.V., Hamlin R.L., Shellhammer L.J., Barrett R.M., Wally R.A., Birchmeier P.A., et al. Variations in hemodynamic parameters and ECG in healthy, conscious, freely moving telemeterized beagles. Cardiovascular Toxicology 2006, 6:51-62.
36. Vargas H.M., Amouzadeh H.R., Engwall M.J. Nonclinical strategy considerations for safety pharmacology: Evaluation of biopharmaceuticals. Expert Opinion on Drug Safety 2013, 12(1):91-102.
37. Walisser J.A., Mitchell A.Z., Bills A.J., Sharma A.K., Latimer K., Taschwer M., et al. Chronic implantation of intravenous/diaphragmatic ECG leads in telemetry-implanted dogs provides high signal quality and minimal pathological sequelae. Journal of Pharmacological and Toxicological Methods 2013, 68:52-61.
38. Wallis R.M. Integrated risk assessment and predictive value to humans of non-clinical repolarization assays. British Journal of Pharmacology 2010, 159:115-121.
39. Ward G., Milliken P., Patel B., McMahon N. Comparison of non-invasive and implanted telemetric measurement of blood pressure and electrocardiogram in conscious beagles. Journal of Pharmacological and Toxicological Methods 2012, 66:106-113.
40. Weirich J., Antoni H. Rate-dependence of anti-arrhythmic and proarrhythmic properties of class I and class III antiarrhythmic drugs. Basic Research in Cardiology 1998, 93(Suppl. 1):125-132.